Neola Medical

22/06/2026

Neola Medical’s rights issue was subscribed to approximately 70 percent, providing the company with approximately SEK 32.5 million before issue costs. The capital will support the continued development of Neola® as the company advances its clinical, regulatory and commercial preparations ahead of the journey toward market launch.

“Thank you to our shareholders, guarantors and new investors for your participation and support. Your commitment strengthens our ability to continue advancing Neola® and our mission to improve care for preterm born babies,” says Hanna Sjöström, CEO of Neola Medical.

16/06/2026

🫁 Imorgon onsdag den 17 juni 2026 är sista dagen att teckna företrädesemissionen i Neola Medical!
Läs mer på nyemissioner.se och teckna redan idag.

https://nyemissioner.se/nyheter/neola-medical-tar-sikte-pa-usa-efter-lyckad-klinisk-studie

Medicinteknikbolaget Neola Medical närmar sig en avgörande fas i utvecklingen av sin produkt för övervakning av för tidigt födda barns lungor. Efter att nyligen ha genomfört sin första kliniska studie på för tidigt födda barn riktas nu fokus mot den amerikanska marknaden, där bolaget ser...

09/06/2026

🫁Redeye Interview: Neola Medical’s rights issue with CEO Hanna Sjöström

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström presents the upcoming rights issue accelerating the journey towards FDA approval and market launch.

Watch the full interview here: https://player.vimeo.com/video/1199757772

Access additional insights from Redeye here: https://www.redeye.se/company/neola-medical

08/06/2026

CEO Hanna Sjöström will deliver a live, on-site presentation at Aktiedagarna in Stockholm on June 10, 2026, at 08:50 CET at Birger Jarl Konferens.
“Neola Medical is entering an important next phase, building on positive safety results from our first clinical pilot study and a sharpened focus on lung collapse detection. At Aktiedagarna, I look forward to presenting our continued preparations toward the U.S. market and how the ongoing rights issue supports this next step,” says Hanna Sjöström, CEO of Neola Medical.

If unable to attend in Stockholm, the presentation will be streamed online at the following link: https://lnkd.in/dSrRd3Sc

The presentation will also be accessible for viewing afterward at www.neolamedical.com

19/05/2026

📣 Neola Medical today released the Q1 report of 2026! 📘👶🏻
“The first quarter of 2026 marked an important milestone for Neola Medical with the completion of enrollment and final results from our first clinical study on preterm born babies. The study represented the first real-world use of Neola® in its intended patient population within neonatal intensive care and confirmed a favorable safety profile across the studied patient population, including very low birth weight preterm born babies.”, says CEO Hanna Sjöström

05/05/2026

Neola Medical today publishes its Annual Report for 2025.

”2025 is the year when Neola is used for the first time for monitoring of the lungs of preterm born babies in intensive care,” says CEO Hanna Sjöström.

Read the full report here:https://storage.mfn.se/56fc16b2-6ee6-47da-9f0d-d02beb396aec/arsredovisning-neola-medical-2025.pdf

28/04/2026

Neola Medical announces rights issue, supported by main shareholders, to fund the next phase until regulatory approval in the U.S.

21/04/2026

🌟 New Redeye Interview with CEO Hanna Sjöström

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical’s first clinical pilot study, key insights and the next phase of clinical development.

🎥 Watch the full interview here:

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical’s first clinical pilot study, key insights and the next phase of clinical development. Watch the full interview here: Redeye Interview Neola Medical Reports P...

21/04/2026

📣 Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development

“We are encouraged by the results confirming the favourable safety profile of Neola®,” says CEO Hanna Sjöström. “Importantly, the study has provided valuable insights into how the technology performs in a clinical setting, helping to define the optimization of the device. We now have a clear understanding of where Neola® can deliver the greatest clinical value, particularly in the detection of life-threatening lung complications in preterm born babies. We are sharpening our product offering by introducing lung collapse detection as a key capability, providing continuous monitoring with decision support for timely intervention.”

💡 Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-reports-positive-safety-results-from-first-clinical-pilot-study-and-advances-towards-next-phase-of-clinical-development/